Overview

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

Status:
Completed
Trial end date:
2020-03-18
Target enrollment:
Participant gender:
Summary
In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium bicarbonate) were analyzed including T cell metabolism and immune phenotype.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Freiburg